Merus has shown positive developments in clinical trials and regulatory meetings with the FDA, resulting in increased collaboration revenue and a more constructive investment outlook. Despite these ...

Merus N.V. (MRUS) is definitely a biotech to keep an eye on in the 1st half of 2024. That's because there are two potential catalysts that, I believe, could cause its stock price to trade higher. It ...

In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Merus (MRUS – Research Report), with a price target of $44.00. Tazeen Ahmad has given a Buy rating ...

In a report released today, Ami Fadia from Needham maintained a Buy rating on Merus (MRUS – Research Report), with a price target of $42.00. Ami Fadia has assigned a Buy rating for Merus’s stock due ...

We recently compiled a list of the Top 10 ADR Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Merus NV (NASDAQ:MRUS) stands against the other ADR stocks.